A total of seven megadeals were announced in the first half of 2019, including four in the second
quarter. This brings us just one shy of the total number of megadeals in all of 2018. Second quarter deal activity was highlighted by AbbVie’s announced acquisition of Allergan for $86.0B. Aside from this megadeal for the Ireland-based Allergan, each of the top ten largest transactions during the quarter had targets based in the U.S.
pwc-pharma-life-sciences-deals-insights-q2-2019
